

If this is an urgent request, please call Chorus Community Health Plans Pharmacy Services.
 Otherwise, please return completed form – Phone: 844-201-4677 or Fax: 844-201-4675

PLEASE TYPE OR PRINT NEATLY
Incomplete responses may delay this request.

Office contact:		Provider specialty:	
Provider first name:		Provider last name:	
Provider phone #:	Provider fax #:	Provider NPI #:	
Patient name:	CCHP Member ID #:	Patient DOB:	Patient age:
Drug requested: Brand Generic	Strength:	Frequency:	Quantity dispensed (including units):

Generic equivalent drugs will be substituted for brand name drugs unless you specifically indicate otherwise.

New medication	If ongoing, please provide start date:	If ongoing, did the member show improvement while on therapy?	Yes
Ongoing medication			No

Diagnosis: _____

Place of administration: Physician's Office	Hospital/Facility	Patient Home	Other
Please provide hospital/facility information: Name: _____ Phone: _____ Address: _____		Please indicate how medication will be billed: Billed directly by the provider via JCODE JCODE: _____ Billed by a pharmacy and delivered to the provider Billed by a pharmacy and delivered to the patient	

Is the prescriber enrolled in the Jynarque REMS program? Yes No

Does the patient have a confirmed diagnosis of ADPKD? Yes No

How many cysts does the patient have in each kidney? _____

Documentation enclosed? Yes No

If family history documentation of ADPKD is unavailable, have other cystic kidney diseases been ruled out? Yes No

Does the patient have rapidly progressing disease? Yes No

What is the patient's most recent estimated GFR (eGFR)? Result: _____ mL/min/1.73m² Date: _____

Does the patient have hypertension? Yes No

If yes, is the patient receiving treatment? Please list: _____

Has the patient had a baseline ALT, AST and bilirubin level checked prior to starting therapy? Yes No

Does the patient have a history of significant liver impairment or injury? Yes No

Is this request for a reauthorization? Yes No

If yes, please include all of the following documentation:

- Documentation showing disease has stabilized or improved while on therapy
- Documentation that the patient's ALT and AST levels are monitored consistently

Most recent estimated GFR (eGFR) Result: _____ mL/min/1.73m² Date: _____

Please provide any additional information in the space below.
